Paris (AP) – Sanofi և GlaxoSmithKline’s potential COVID-19 vaccine has elicited strong immune responses in all adult age groups after an early reversal in initial trials, boosting optimism that the shot could join the fight this year.
After two doses of the vaccine candidate, participants showed neutralizing antibodies in line with antibodies found in people who had recovered from the disease, according to the results of a Phase 2 trial released on Monday. The pharmacists said they plan to start phased testing and production in the coming weeks and hope to receive regulatory approval for the vaccine by the end of 2021.
Regulators have already approved a number of COVID-19 vaccines, although experts say more is needed as global health authorities compete to vaccinate their residents against an epidemic that has already killed more than 3.3 million people and caused economic devastation. :
The Sanofi-GSK vaccine was an important part of the EU Vaccine Strategy, especially supported by the government of French President Emanuel Macron. But researchers had to redesign it after early testing after it caused an insufficient immune response in the elderly.
The Sanofi-GSK candidate joins about a dozen vaccines that are currently being tested in the late stages. The companies plan to produce up to 1 billion doses a year, they have signed contracts for supply to the United States, Canada and developing countries. Public health experts say several vaccines will be needed to end the epidemic because of the challenges of producing and distributing enough doses to vaccinate billions of people.
“We know there is a need for more vaccines, especially as variants emerge, and the need for ‘effective’ strong vaccines is growing at a normal temperature,” said Thomas Triomf, head of the Sanof vaccine division.
The results, released on Monday, came from Phase 2 trials involving 722 volunteers aged 18 to 95 who were recruited in the United States and Honduras.
The vaccine showed even stronger antibodies in people who had already recovered from the virus. Sanofi says this makes it a potentially strong candidate as a future booster for those who have already been vaccinated with competing products.
According to the companies, about 37,000 participants from around the world will take part in the late trial. They plan to study its effectiveness against a version of the virus that was first discovered in South Africa as much as possible.
Following the initial setback, Sanofi entered into agreements to help bottle or produce competing vaccines developed by Pfizer, Moderna և Johnson & Johnson. Advances in the Sanofi-GSK vaccine will not disrupt those production plans, Triomphe said.